InCarda Therapeutics Obtains $5,000,000 Series A Financing Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a22cfc41-5d0f-4119-adf9-769efe4afc17
Date 4/29/2015
Company Name InCarda Therapeutics
Mailing Address 150 Post Street San Francisco, CA 94108 USA
Company Description Here at InCarda, we see a better way. We see a future that includes improved quality of care for patients with acute cardiac conditions. We are committed to developing transformative therapies that patients can use themselves in the first moments of acute cardiovascular symptoms.
Proceeds Purposes Proceeds from the financing will be used to further the company’s lead cardiovascular program for an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF).